News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,807 Results
Type
Article (14260)
Company Profile (105)
Press Release (259434)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88271)
Career Advice (465)
Deals (15392)
Drug Delivery (73)
Drug Development (36714)
Employer Resources (50)
FDA (6382)
Job Trends (6232)
News (150699)
Policy (14129)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23320)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6573)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1317)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32018)
Collaboration (725)
Compensation (325)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1821)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33459)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (38977)
Executive appointments (528)
FDA (7480)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (428)
Gene editing (70)
Generative AI (18)
Gene therapy (165)
GLP-1 (439)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3575)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (842)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3448)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1302)
Medtech (1309)
Mergers & acquisitions (9899)
Metabolic disorders (434)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (887)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29741)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8305)
Phase 2 (13518)
Phase 3 (12211)
Pipeline (1904)
Policy (135)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2659)
Recruiting (18)
Regulatory (10955)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (177)
Last 30 days (657)
Last 365 days (10404)
2026 (951)
2025 (10712)
2024 (12498)
2023 (14246)
2022 (19557)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13889)
2016 (13132)
2015 (15474)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20895)
Australia (2687)
California (3177)
Canada (1481)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40869)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2586)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (906)
North Carolina (619)
North Dakota (2)
Northern California (1447)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1387)
Tennessee (53)
Texas (454)
United States (12668)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
273,807 Results for "micurx pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease
January 29, 2026
·
2 min read
MicuRx To Present New Data At 7th World Bronchiectasis Conference
Shanghai MicuRx Pharmaceutical Co., Ltd. announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland.
June 19, 2024
·
2 min read
Press Releases
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
April 8, 2025
·
1 min read
Drug Development
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the expected goals.
June 6, 2024
·
5 min read
Press Releases
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
February 25, 2025
·
4 min read
Press Releases
FDA Grants Orphan Drug Designation to MicuRx’s MRX-5 for NTM Infections
January 2, 2025
·
2 min read
News
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
October 18, 2024
·
2 min read
Press Releases
MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections
October 8, 2024
·
2 min read
Press Releases
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China
December 2, 2024
·
3 min read
Biotech Bay
MicuRx announces poster presentation and participation in ID Week 2023 Conference
MicuRx Pharmaceuticals, Inc. announces that a poster on our preclinical product, MRX-6038, will be presented at ID Week entitled “In vitro Potency of a Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium abscessus.”
October 11, 2023
·
2 min read
1 of 27,381
Next
